Request Discount

Erythropoietin Drugs Market (Drug Class - Biologics, and Biosimilars; Product - Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa, and Other Products; Applications - Cancer, Hematology, Renal Diseases, and Neurology): Global Industry Analysis, Trends, Size, Share and Forecasts to 2025

  • Published : August, 2019

  • Rep Id : HC0648

  • Category : Healthcare & Medical Devices

  • Status : Published

This report provides exclusive insights into the COVID-19 impact on the Erythropoietin Drugs Market. The detailed analysis provides information about the impact of the outbreak on the demand and supply conditions, trends and forecasts of the Erythropoietin Drugs Market. Moreover, the impact analysis covers the study of the COVID-19 on the supply chain of Erythropoietin Drugs Market. The sectoral impact shall provide insights into both short term and long term effects of the pandemic on the related and support industries.

A recent report published by Infinium Global Research on erythropoietin drugs market provides in-depth analysis of segments and sub-segments in the global as well as regional erythropoietin drugs market. The study also highlights the impact of drivers, restraints, and macro indicators on the global and regional erythropoietin drugs market over the short term as well as long term. The report is a comprehensive presentation of trends, forecast and dollar values of the global erythropoietin drugs market. According to the report, the global erythropoietin drugs market is projected to grow at a CAGR of 10.2% over the forecast period of 2019-2025.


Market Insight

Erythropoietin (EPO) was the first recombinant deoxyribonucleic acid (DNA) drug to arrive common medical use in the U.S. Medicare is by far the largest payer for EPO because Medicare covers about 93 percent of dialysis patients. As a result of Medicare coverage and payment regulations significantly influence the financial environment physicians and dialysis facilities face in attempting to balance the best care for patients with the fiscal reality. Hemoglobin levels and the dose of erythropoiesis-stimulating agents (ESAs) have increased in hemodialysis patients in the United States. It is a glycoprotein hormone that controls erythropoiesis or production of red blood cells. They are used in the treatment of different diseases like cancer and chronic renal diseases.


An increasing number of patients suffering from anemic condition induced due to cancer, HIV and End-Stage Renal Disease (ESRD) treatment is the major driving factor for the erythropoietin drugs market. Furthermore, factors such as the presence of large patient populations, patent expiration of biologics and an increase in the availability of biosimilars are other driving factors for the market growth. The use of EPO is held to increase oxygen absorption, reduce fatigue and improve endurance by increasing the rate of red cell production. It is also held that EPO increases the metabolism and the healing process of muscles because the extra red cells carry more oxygen and nutrients. Rising incidence of chronic kidney disease (CKD), cancer and HIV fueling the growth of the market. However, the high cost of EPO drugs is the major restraint factor for the erythropoietin drugs market. Moreover, patent expiration of major biologics during the coming years are anticipated to provide wide growth opportunities to the market players.


Geographically, North America dominates the global erythropoietin drugs market owing to continuously increasing cancer population and patient suffering from renal diseases in this region. Europe is the second-largest market for erythropoietin drugs followed by Asia-Pacific.


Segment Covered

The report on global erythropoietin drugs market covers segments such as drug class, product, and applications. On the basis of drug class, the sub-markets include biologics, and biosimilars. On the basis of product, the sub-markets include epoetin-alfa, epoetin-beta, darbepoetin-alfa, and other products. On the basis of applications, the sub-markets include cancer, hematology, renal diseases, and neurology.

Global Erythropoietin Drugs Market


Companies Profiled:

The report provides profiles of the companies in the market such as Hospira Inc., Johnson & Johnson, Amgen Inc., Roche Holding AG, LG Life Sciences Ltd., Biocon Limited, Celltrion, Inc., Intas Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Ranbaxy Laboratories Ltd., and other companies.


Report Highlights:

The report provides deep insights into the demand forecasts, market trends, and micro and macro indicators. In addition, this report provides insights into the factors that are driving and restraining the growth in this market. Moreover, The IGR-Growth Matrix analysis given in the report brings an insight into the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter's five forces analysis and DRO analysis of erythropoietin drugs market. Moreover, the study highlights current market trends and provides forecast from 2019-2025. We also have highlighted future trends in the market that will affect the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight into the market share of the leading players.

Other Reports in This Category
24 hour delivery through email
9923950043 Monday to Frieday 9am-7pm
looking for discount